Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : Ginkgo Bioworks raises $350 million fund for biotech spinouts

share with twitter share with LinkedIn share with facebook
share via e-mail
10/09/2019 | 11:37am EDT
Jason Kelly, Co-Founder and CEO of Ginkgo Bioworks, speaks during the Milken Institute's 22nd annual Global Conference in Beverly Hills

(Reuters) - Biotechnology start-up Ginkgo Bioworks said on Wednesday that it had raised a $350 million fund to more easily invest in spinout ventures that use its bio-engineering technology in a variety of industries that are just starting to use cutting edge biology.

Dubbed the Ferment Fund, the investment vehicle will invest in two to three companies a year, Ginkgo Chief Executive Officer Jason Kelly said in an interview. Ginkgo hopes such investments will help increase the use of its technology.

Ginkgo has used this strategy in the past. In 2017, it formed a joint venture with Bayer AG to develop bacteria that can perform similar functions to fertilizers without the associated pollution. Earlier this year, it launched Motif Foodworks, a company developing animal-free food ingredients, with investment from agricultural merchant Louis Dreyfus Co.

General Atlantic, Viking Global Investors, and Bill Gates' investment firm Cascade Investment participated in the financing.

Ginkgo is one of the world's largest privately held biotechnology firms. It works to make biological engineering cheaper and more accessible, particularly in fields where biotechnology is not yet widespread, by serving as a platform that allows customers to bypass the expensive overhead associated with doing their own scientific research.

This includes large corporations working in industries such as agriculture, cosmetics, foods, and textiles, sectors where biotechnology could have useful applications but where its use is in early stages.

"As computers got cheaper, a whole host of applications became accessible. We think the same thing is true for biology" Kelly said. "The big thing we’re tying to accomplish now is build an ecosystem for people to build apps essentially for cells."

The new fund follows a $290 million funding round the company completed in September, which brought its total financing to $719 million and its valuation to $4 billion.

Despite the large amount of investment for a biotechnology company, Kelly said Ginkgo has no immediate plans to go public and hopes to have several successful spinouts first.

"What we want to be able to tell public investors is that we are the platform to program cells,” he said.

(This story corrects "developing animal-free food ingredients" instead of "developing meat-free foods" in paragraph 3)

(Reporting by Rebecca Spalding in New York; Editing by David Gregorio)

By Rebecca Spalding

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER AG
10/17BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
10/16Factbox - How are businesses preparing for a 'no-deal Brexit'?
10/16ATOS : Signs Contract With Bayer for Digital Workplace Services
10/16BAYER : Animal Health and VLPbio sign global collaboration agreement
10/15BAYER : U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill..
10/15J&J's Courtroom Losses Pile Up -- WSJ
10/14Early Blizzard Wallops Vulnerable Crops
10/14J&J'S JANSSEN : FDA OK's Xarelto in Acutely Ill Medical Patients
10/14BAYER : U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill..
10/14Johnson & Johnson's Legal Challenges Mount
More news
Financials (EUR)
Sales 2019 46 036 M
EBIT 2019 7 933 M
Net income 2019 3 095 M
Debt 2019 37 372 M
Yield 2019 4,36%
P/E ratio 2019 21,1x
P/E ratio 2020 13,4x
EV / Sales2019 2,13x
EV / Sales2020 2,01x
Capitalization 60 840 M
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 79,26  €
Last Close Price 65,24  €
Spread / Highest target 88,5%
Spread / Average Target 21,5%
Spread / Lowest Target -40,6%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG7.73%67 773
JOHNSON & JOHNSON5.52%337 021
ROCHE HOLDING AG18.49%250 869
MERCK AND COMPANY10.82%216 813
PFIZER-16.47%201 662
NOVARTIS15.95%198 751